What are the specific functions and efficacy of Upatinib/Refu?

Upadacitinib (Upadacitinib) is a selective JAK1 inhibitor mainly used to treat a variety of immune-mediated diseases. JAK1 is a member of the Janus kinase family and is involved in the transmission of cytokine signals. By inhibiting JAK1, upadatinib can intervene in multiple cellular processes related to immune response and inflammation, with significant therapeutic effects. Its role and efficacy have been verified in multiple clinical studies, especially in diseases such as rheumatoid arthritis (RA), atopic dermatitis (AD), and psoriatic arthritis (PA).

1. Treatment of Rheumatoid Arthritis（RA)

Rheumatoid arthritis is a chronic autoimmune disease characterized by joint inflammation, swelling, and pain. By inhibiting JAK1, upadatinib can effectively reduce the inflammatory response caused by cytokines IL-6, IL-7, etc., reduce joint swelling and pain, and improve the patient's joint function. Clinical studies have shown that upadatinib can significantly improve symptoms and reduce joint damage in RA patients, even in patients who are ineffective in treatment with traditional disease-modifying antirheumatic drugs (DMARDs).

2. Treat psoriatic arthritis (PA)

Psoriatic arthritis is arthritis associated with psoriasis. Symptoms include joint swelling and morning stiffness. Upadatinib has significant efficacy in the treatment of psoriatic arthritis. By blocking JAK1 signaling, upadatinib reduces inflammation, reduces joint swelling and pain, and improves patients' mobility and quality of life. Studies have shown that upadatinib can effectively relieve clinical symptoms of psoriatic arthritis and improve skin lesions in some patients.

3. Other indications

Upadatinib is also used to treat atopic dermatitis (AD), ulcerative colitis (UC), ankylosing spondylitis, Crohn's disease and other immune-mediated diseases. By inhibitingJAK1, upadatinib can effectively reduce the inflammatory response in these diseases and improve patients' symptoms and quality of life.

Keyword tag:

upatinib, Ruifu, Upadacitinib, JAK1 inhibitor, rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, immunosuppression, inflammatory response

Reference materials:https://www.ncbi.nlm.nih.gov/books/NBK572088/